Mercury Laboratories Ltd vs Parmax Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 11, 2026

Key Highlights

The Latest Trading Price of Mercury Laboratories Ltd is ₹ 799 as of 07 May 15:30 . The P/E Ratio of Mercury Laboratories Ltd changed from 14.4 on March 2021 to 31.3 on March 2025 . This represents a CAGR of 16.80% over 5 yearsThe P/E Ratio of Parmax Pharma Ltd changed from 21 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Mercury Laboratories Ltd changed from ₹ 77.11 crore on March 2021 to ₹ 98.29 crore on March 2025 . This represents a CAGR of 4.97% over 5 yearsThe Market Cap of Parmax Pharma Ltd changed from ₹ 13.28 crore on March 2021 to ₹ 15.8 crore on March 2025 . This represents a CAGR of 3.54% over 5 years The revenue of Mercury Laboratories Ltd for the Dec '25 is ₹ 18.66 crore as compare to the Sep '25 revenue of ₹ 19.8 crore. This represent the decline of -5.76% The revenue of Parmax Pharma Ltd for the Dec '25 is ₹ 4.33 crore as compare to the Sep '25 revenue of ₹ 2.54 crore. This represent the growth of 70.47% The ebitda of Mercury Laboratories Ltd for the Dec '25 is ₹ 2.44 crore as compare to the Sep '25 ebitda of ₹ 2.92 crore. This represent the decline of -16.44% The ebitda of Parmax Pharma Ltd for the Dec '25 is ₹ -0.19 crore as compare to the Sep '25 ebitda of ₹ -1.58 crore. This represent the decline of -87.97% The net profit of Mercury Laboratories Ltd changed from ₹ 0.34 crore to ₹ 1 crore over 7 quarters. This represents a CAGR of 85.24% The net profit of Parmax Pharma Ltd changed from ₹ 0.01 crore to ₹ -0.73 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Mercury Laboratories Ltd changed from 7.87 % on March 2021 to 13.38 % on March 2025 . This represents a CAGR of 11.20% over 5 yearsThe Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Mercury Laboratories Ltd

Mercury Laboratories Limited, the registered partnership firm started its business activity in year 1962.
Subsequently, it converted into Private Limited Company & incorporated in February, 1982.
Later, it converted into Limited Company in 1992 in Maharashtra.
The Company has obtained ISO 9001:2008 registrations.
It is engaged into the manufacturing and export of wide range of Pharmaceutical items.

About Parmax Pharma Ltd

Incorporated in November, 1994, Parmax Pharma Limited (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations.
The Company has manufacturing facilities approved by Indian regulatory bodies such as CDSCO, State FDA, and operates under GMP-compliant systems. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
The Company then discontinued their business activities for few years due to various reasons.
Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

FAQs for the comparison of Mercury Laboratories Ltd and Parmax Pharma Ltd

Which company has a larger market capitalization, Mercury Laboratories Ltd or Parmax Pharma Ltd?

Market cap of Mercury Laboratories Ltd is 95 Cr while Market cap of Parmax Pharma Ltd is 12 Cr

What are the key factors driving the stock performance of Mercury Laboratories Ltd and Parmax Pharma Ltd?

The stock performance of Mercury Laboratories Ltd and Parmax Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Mercury Laboratories Ltd and Parmax Pharma Ltd?

As of May 11, 2026, the Mercury Laboratories Ltd stock price is INR ₹799.0. On the other hand, Parmax Pharma Ltd stock price is INR ₹32.99.

How do dividend payouts of Mercury Laboratories Ltd and Parmax Pharma Ltd compare?

To compare the dividend payouts of Mercury Laboratories Ltd and Parmax Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.